p53 Tumor Suppressor Protein and H-RAS Oncogene in Maxillofacial Tumors: Immunohistochemical and Genetic Investigation, Induction Chemotherapy Response and Prognosis Evaluation

REFERENCES

• Aisner J, Hiponia D, Jacobs M, Belamo CP. Combined modalities of head and neck cancer. Semin Oncol 1995; 22, 03, Suppl 6: 28-34.
   Google Scholar
• Haribhakti H, Kavorama N, Tibrewala AN. Oral cavity reconstruction: an objective assessment of the function. Head-Neck Cancer 1993; 15: 119–122.
   PubMed Web of Science ®Google Scholar
• Wei FC, Seah CS, Tsai YC, Liu SJ, Tsai MS. Fibula osteoseptocutaneous flap for reconstruction of composite mandibular defect. Plast Reconstr Surg 1994; 93: 294.
   PubMed Web of Science ®Google Scholar
• Wenig BL. The role of surgery in head and neck cancer: standard care and new horizons. Semin Oncol 1994; 21: 289–295.
   PubMed Web of Science ®Google Scholar
• McDonald JS, Jones H, Pavelic ZP, Pavelic LJ, Stambrook PJ, Gluckman JL. Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck. J Oral Pathol Med 1994; 23 (8): 342–346.
   PubMed Web of Science ®Google Scholar
• Nylander K, Stenling R, Gustofsson H, Zackrisson B, Roos G. p53 Expression and cell proliferation in squamous cell carcinomas of the head and neck. Cancer 1995; 75,1: 87–93.
   PubMed Web of Science ®Google Scholar
• Hainaut P. The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol 1995; 7: 76–82.
   PubMedGoogle Scholar
• Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821–1828.
   PubMed Web of Science ®Google Scholar
• Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329, 18: 1318–1327.
   PubMed Web of Science ®Google Scholar
• Lee JM, Bernstein A. p-53 Mutations increase resistance to ionizing radiation. Poc Natl Acad Sci U5A1993; 90: 5742–5746.
   PubMed Web of Science ®Google Scholar
• Martin L, Smith LS, Fornace AJJr. Genomic instability and the role of p-53 mutations in cancer cells. Curr Opin Oncol 1995; 7: 69–75.
   PubMedGoogle Scholar
• smith NIL, Fornace AJ. Genomic instability and the role of p53 mutations in cancer cells. Curr Opin Oncol 1995; 7: 69–75.
   PubMedGoogle Scholar
• Kinzler KW, Vogelstein B. Clinical implications of basic research: cancer therapy meets p53. N Engl J Med 1994; 331, 1: 49–50.
   PubMed Web of Science ®Google Scholar
• Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2, 1: 72–79.
   PubMed Web of Science ®Google Scholar
• Leedy DA, Trune DR, Kronz JD, Weidner N, Cohen JI. Tumor angiogenesis, the p53 antigen, and cervical metas-tasis in squamous carcinoma of the tongue. Otolaryngol Head Neck Surg 1994; 111 (4): 417–422.
   PubMed Web of Science ®Google Scholar
• Nylander K, Stenling R, Gustafsson H, Zackrisson B, Roos G. p53 expression and cell proliferation in squamous cell carcinomas of the head and neck. Cancer 1995; 75, 1: 87–93.
   PubMed Web of Science ®Google Scholar
• Sakai E, Rikimaru K, Ueda M, et al. The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Int J Cancer 1992; 52 (6): 867–872.
   PubMed Web of Science ®Google Scholar
• Scully C. Oncogenes, onco-suppressors, carcinogenesis and oral cancer. Br Dent J 1992; 173 (2): 53–59.
   PubMedGoogle Scholar
• Sidransky D. Molecular genetics of head and neck cancer. Curr Opin Oncol 1995; 7: 229–233.
   PubMedGoogle Scholar
• Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 4477-4480.
   Google Scholar
• Field JK. The role of oncogenes and tumours-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. J Royal Soc Med, 1995; 88: 35–39.
   PubMed Web of Science ®Google Scholar
• St. Croix B, Kerbel R. Cell adhesion and drug resistance in cancer. Curr Opin Oncol 1997; 9: 549–556.
   PubMedGoogle Scholar
• Martin SJ, Green DR. Apoptosis as a goal of cancer therapy. Curr Opin Oncol 1994; 6: 616–621.
   PubMedGoogle Scholar
• Breu RL, Clayman GL. Gene therapy for head and neck cancer. Curr Opin Oncol 1996; 8 (3): 227–231.
   PubMedGoogle Scholar
• Cutilli T, Papola F, Corbacelli A. p53 overexpression and mutation, chemoresistance and patient survival in oral and maxillofacial squamous cell carcinomas. J Chemother 1997; 9, 2: 123–124.
   PubMedGoogle Scholar
• Cutilli T, Di Emidio P, Papola F, Corbacelli A. Oro-maxillofacial tumours in advanced stage: immunohistochemical study, genetic analysis and response to the neoadjuvant chemotherapic treatment. J Exp Clin Res 1997; 16, 2: 166–168.
   Google Scholar
• Nees M, Homann N, Discher H, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 1993; 53,15: 4189–4196.
   PubMedGoogle Scholar
• Bradford CR, Zhu S, Wolf CT, et al. Overexpression of p53 predicts organ preservation using induction chemo-therapy and radiation in patients with advanced laryngeal cancer. Otolaryngol Head Neck Surg 1995; 113 (4): 408–412.
   PubMed Web of Science ®Google Scholar
• Koch WM, Boyle JO, Mao L, Hakim J, Hruban RH, Sidransky D. p53 gene mutations as markers of tumor spread in synchronous oral cancers. Arch Otolaryngol Head Neck Surg 1994; 120 (9): 943–947.
   PubMedGoogle Scholar
• Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2, 9: 985–991.
   PubMed Web of Science ®Google Scholar
• Hemmer J, Schon E. Anticancer drug action assessed by serial DNA flow cytometry during induction chemotherapy in oral squamous cell carcinoma: impacts on the development of individualized treatment strategies. Chemotherapy 1995; 41 (3): 214–221.
   PubMed Web of Science ®Google Scholar
• Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol 1994; 21: 311–319.
   PubMed Web of Science ®Google Scholar
• Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5 (6): 521–526.
   Google Scholar
• Wang HM, Wang CH, Chen JS, et al. Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer. J Formos Med Assoc 1995; 94 (3): 87–94.
   PubMedGoogle Scholar
• Lore JM, Diaz-Ordaz E, Spaulding M, et al. Improved survival with preoperative chemotherapy followed by resection uncompromised by tumor response for advanced squamous cell carcinoma of head and neck. Am J Surg 1995; 170 (5): 506–511.
   PubMed Web of Science ®Google Scholar
• Maipang T, Maipang M, Geater A, Panjapiyakul C, Watanaarepornchai S, Punperk S. Combination chemo-therapy as induction therapy for advanced resectable head and neck cancer. J Surg Oncol 1995; 59 (2): 80–85.
   PubMed Web of Science ®Google Scholar
• Forastiere AA. Paclitaxel (taxol) for the treatment of head and neck cancer. Semin Oncol 1994; 21 (5 suppl 8): 49-52.
   Google Scholar
• Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5 (6): 533–537.
   PubMed Web of Science ®Google Scholar
• Rosenthal DI, Carbone DP. Taxol plus radiation for head and neck cancer. AADE Ed J 1995; 5 (2): 46–54.
   Google Scholar
• Liggett W Jr, Forastiere AA. Chemotherapy advances in head and neck oncology. Sem Surg Oncol 1994; 11 (3): 265–271.
   Google Scholar
• Irish JC, Bernstein A. Oncogenes in head and neck cancer. Laryngoscope 1993; 103: 42–52.
   PubMed Web of Science ®Google Scholar
• Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–967.
   PubMed Web of Science ®Google Scholar
• Lippman SM, Spitz MR, Huber MH, Ki Hong W. Strategies for chemoprevention study of premalignancy and second primary tumors in the head and neck. Curr Opin Oncol 1995; 7: 234–241.
   PubMedGoogle Scholar